Answers are grounded in this paper and cite their sources.
Using the HIV-1 protease binding mode of MK-8718 and PL-100 as inspiration, a novel aspartate binding bicyclic piperazine sulfonamide core was designed and synthesized. The resulting HIV-1 protease inhibitor containing this core showed an 60-fold increase in enzyme binding affinity and a 10-fold increase in antiviral activity relative to MK-8718 .
No takes yet. Share an insight, caveat, or question.
Bungard et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: